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Gy daily fractions for oropharynx/oral cavity and positive lymph 
nodes. Lower doses were used for patients treated with concomitant 
chemotherapy: 66 Gy in 2.2 Gy daily fractions for tumor and 60 Gy in 
2 Gy daily fractions for oropharynx/oral cavity and positive lymph 
nodes. Negative lymph nodes were irradiated with equal dose for both 
groups: 54 Gy in 1.8 Gy daily fractions. Chemotherapy (either 
carboplatin 100mg/m2 or cisplatin 80 mg/m2) was given intravenously 
every 3 weeks. 
Results: The median follow-up was 24 months (range 3-53). Complete 
response rate for the oropharynx and the oral cavity group was 87% 
and 87.5% , respectively. The 1 and 2-year Overall Survival (OS) and 
Disease Free Survival (DFS) rate for the oropharynx group was 80%, 
73.3%, 73.3% and 73.3% respectively. For the oral cavity group, 1 and 
2-year OS and DFS rates were 62.5%. Concerning acute toxicity, no 
patient developed grade ≥3. G2 mucositis, dysphagia and dermatitis 
rates were 87%, 69.6% and 47.9%, respectively. Concerning late 
toxicity, maximum grade observed was G2 xerostomia in 5.6% of 
cases.  
Conclusions: HT appears to achieve encouraging clinical outcomes in 
terms of response, survival and toxicity rates.  
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Purpose/Objective: Incidence of Oral Cavity Squamous Cell 
Carcinoma (OCSCC) in India is amongst the highest in the world. The 
analysis highlights time lags in presentation and treatment along with 
disease control outcomes.  
Materials and Methods: Unselected case notes of 56 patients with 
OCSCC who underwent surgery at Tata Medical Center (TMC), between 
May 2011 to October 2012 were analysed. Time from presentation to 
consultation at TMC, consultation to first surgery, T, N, M and overall 
stage (AJCC 7) were analysed. Time lag between surgery to adjuvant 
treatment (radiotherapy (RT) or chemoradiotherapy (CTRT) to a dose 
of 60-63Gy in 30 fractions), disease free survival, distant metastases 
free survival, local recurrence and cases lost to follow up rates were 
calculated after a median follow up of 6 months. 
Results: The mean age was 52.9 years with 25 (44.6%) patients having 
oral tongue, 18 (32.14%) buccal mucosa disease. On presentation, 14 
(25%), 13 (23.2%), 23 (41%) and 5 (8.9%) patients had T4, T3, T2 and 
T1 disease respectively. 12 (21.4%), 15 (26.7%) and 5 (8.9%) had N1, 
N2 or N3 disease. 29 (51.7%), 16 (28.5%), 9 (16%) cases presented with 
stage IV, III and II disease. The time lag between first symptom to that 
when patient was seen in TMC was 4.5months (range 0-24 months). 5 
(8.9%) cases received neo adjuvant chemotherapy prior to surgery. 
Time lag between when seen at TMC and when surgery was performed 
was 1 month (range 0-3months) with 91% cases requiring some form of 
reconstructive procedure during surgery. Median time between 
surgery and adjuvant treatment was 1.5 months (range1-2 months). 27 
(48.2%) cases completed concurrent CTRT with a platinum agent, 26 
(46%) received RT only whist 2 patients refused to have RT and one 
received RT outside the country. 7 cases (12.5%) developed local 
recurrence. 4 (7.1%) cases developed distant metastases of which 
3(75%) developed both local and distant disease. 45 (80.3)% patients 
were alive at 6 months, 3 patients were lost to follow up. 4 deaths 
occurred within 1 month post treatment prior to any follow up and has 
been attributed to aspiration related symptoms. 
Conclusions: Indian patients present late, with more advanced 
disease at a younger age, majority with a significant time lag prior to 
presenting to the tertiary center. Although patients complete their 
treatment lack of community support could result in toxicities prior to 
the first follow up (1 month post RT) requiring early intervention by a 
community nurse. Early local or distant metastases in this patient 
group could raise the possibility of an aggressive biological subtype of 
OCSCC.  
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Purpose/Objective: To assess efficacy of geftinib along with 
chemoradiation (cisplatin + radiotherapy) in comparision to 
chemoradiation alone in management of locally advanced head and 
neck cancer. 
Materials and Methods: 60 previously untreated histologically proven 
patients of squamous cell carcinoma of head and neck cancer 
attending department of radiotherapy, SMS hospital, Jaipur from june 
2011 to may 2012 were taken and divided into two groups- control (30 
patients) and study (30 patients). The control group received cisplatin 
30mg/m2 iv weekly along with radiotherapy, starting from day 1 of 
radiotherapy. The study group received gefitinib 250 mg po starting 1 
week prior to commencement or radiotherapy followed by cisplatin 
30mg/m2 iv weekly along with radiotherapy, starting from day 1 of 
radiotherapy till its completion. Dose of radiotherapy was 66Gy/33Fr/ 
6.3 weeks. Patients were followed monthly upto 6 months. 
Results: The acute and late radiation toxicity on skin, mucosa and 
hemogram was variable in control and study groups but more in study 
group. Combined for all T stage tumors complete response (CR) for 
control and study groups was 24 (80%) and 17 (56%) respectively. The 
overall response (tumor+nodal response) for all stages was found 
statistically non-significant. Disease status at 6th month follow up in 
control and study group was: no evidence of disease- 21 (70%) versus 
27(90%), residual disease- 8 (27%) versus 3(10%). At the median follow 
up of 15 months, 16 patients of study group were on follow up,11 of 
which had complete response and 5 had recurrent disease. In control 
group, 10 patients were on follow up of which 7 had complete 
response and 3 had recurrent disease. 
Conclusions: Chemoradiation remains mainstay of treatment for head 
and neck carcinoma patients. EGFR is the most expressed receptor in 
squamous cell carcinoma of head and neck. The present study shows 
that targeted therapy with gefitinib (EGFR tyrosine kinase inhibitor) 
and chemoradiation is well tolerated with some enhanced but 
manageable toxicities and has shown to improve local control and 
survival in locally advanced head and neck cancer.  
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Purpose/Objective: The aim of the study was to analyze the overall 
outcomes, patterns of failure and toxicities of postoperative, daily 
image guided head and neck helical tomotherapy (HT). 
Materials and Methods: 86 patients (67 male and 19 female) were 
treated with HT between June 2007 and August 2010 at our 
institution. Overall, the median age was 58 years. The majority of 
patients had a T2(48%,n=41);N2(55%,n=47) tumor, with a total of 30 
patients with ECE. The median prescribed dose to the PTV was 64 Gy. 
42 patients underwent conconcomitant platinum based chemotherapy.  
Results: Median follow-up time was 32 months. 2-year (3-year) overall 
survival, disease-free survival, and locoregional control were 
81%(73%), 77%(63%), and 82%(74%), respectively. Overall 15 patients 
developed a locoregional failure (12 local, 3 regional): 14 infield , 1 
marginal field. 13 patients developed distant metastasis. At 2 years 2 
patients had grade 3 dysphagia (CTCAE v4.0). No further grade 3/4 
toxicitieswere observed. 
Conclusions: Our results show that daily image guided helical 
tomotherapy is effective and safe in terms of local disease control and 
avoidance of persistent grade 3/4 late toxicities. 
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Purpose/Objective: Radiation induced thyroid abnormality after 
radiotherapy (RT) of nasopharyngeal cancer (NPC) has been reported 
in many studies. Apart from the thyroid gland, the pituitary gland is 
also usually irradiated to high dose for patients with skull base 
involvement. Since the thyroid function is controlled by the pituitary 
gland through the hypothalamic-pituitary-thyroid axis, the hypothesis 
of this study was that the combined effect of high radiation dose to 
the thyroid and pituitary glands would increase the risk of thyroid 
abnormality.  
Materials and Methods: 65 NPC patients with stages II to IV treated by 
RT were recruited. Before RT, baseline thyroid hormone levels of each 
patient including fT3, fT4 and TSH were taken. A 7-beam intensity 
modulated radiotherapy (IMRT) plan was generated for each patient 
following the local planning protocol. The doses to the thyroid and 
pituitary glands were calculated by generating their dose volume 
histograms (DVH). The patients were divided into 4 categories 
according to the doses to the thyroid and pituitary glands, where 'high 
